ArticleJournal of diabetes research2025
Correlation of Serum Growth Differentiation Factor 15 With Metabolic Syndrome and Its Components in Patients With Type 2 Diabetes Mellitus.
Article in Journal of diabetes research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correlation of Serum Growth Differentiation Factor 15 With Metabolic Syndrome and Its Components in Patients With Type 2 Diabetes Mellitus.Journal of diabetes research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study is to explore the association between serum growth differentiation factor 15 (GDF15) and metabolic syndrome (MS), as well as its components in patients with Type 2 diabetes mellitus (T2DM). Patients and Methods: Data on 125 patients with T2DM admitted to the Department of Endocrinology of the Second People's Hospital of Hefei City between August 2022 and June 2023 were retrospectively collected. According to the diagnostic criteria of MS, the patients were divided into two groups: T2DM alone (67 cases) and T2DM combined with MS (58 cases). General conditions and laboratory indicators of the patients were collected to analyze the correlation of GDF15 expression in T2DM and combined MS. Results: The GDF15 level in the T2DM with MS group was higher than that in the T2DM group ( Conclusion: Serum GDF15 is strongly correlated with T2DM combined with MS and its components, and elevated GDF15 is valuable for the diagnosis of T2DM combined with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.